| Jun'18 | Jun'17 | |||||
|---|---|---|---|---|---|---|
Net sales to third parties | ||||||
13,158 | 12,242 | |||||
Other revenues | ||||||
294 | 252 | |||||
Cost of goods sold | ||||||
4,477 | 4,258 | |||||
Gross profit from continuing operations | ||||||
8,975 | 8,236 | |||||
Selling, General and Administration | ||||||
4,193 | 3,806 | |||||
Research and Development | ||||||
2,276 | 2,062 | |||||
Other income | ||||||
543 | 480 | |||||
Other expense | ||||||
565 | 568 | |||||
Operating income from continuing operations | ||||||
2,484 | 2,280 | |||||
Income from associated companies | ||||||
5,932 | 215 | |||||
Interest expense | ||||||
244 | 192 | |||||
Other financial income and expense | ||||||
47 | 12 | |||||
Income before taxes from continuing operations | ||||||
8,219 | 2,315 | |||||
Taxes | ||||||
451 | 336 | |||||
Net income | ||||||
7,768 | 1,979 | |||||
Attributable to | ||||||
Shareholders of Novartis AG | ||||||
7,768 | 1,980 | |||||
Non-controlling interests | ||||||
0 | -1 | |||||
Weighted average number of shares outstanding used in the basic earnings per share | ||||||
2,327 | 2,354 | |||||
Basic earnings per share [abstract] | ||||||
Total basic earnings per share | ||||||
3.34 | 0.84 | |||||
Adjusted weighted average number of ordinary shares outstanding | ||||||
2,346 | 2,373 | |||||
Diluted earnings per share [abstract] | ||||||
Total diluted earnings per share | ||||||
3.31 | 0.83 | |||||